UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Volltextzugriff (PDF)

The promise of personalized medicine for hidradenitis suppurativa

British journal of dermatology (1951), 2023-01, Vol.188 (1), p.3-3

Okun, Martin M

2023

Volltextzugriff (PDF)

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Acta dermato-venereologica, 2018-11, Vol.98 (10), p.932-937

2018

Volltextzugriff (PDF)

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

Journal of dermatology, 2015-11, Vol.42 (11), p.1042-1052

2015

Volltextzugriff (PDF)

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Health and quality of life outcomes, 2006-09, Vol.4 (1), p.71-71, Article 71

2006

Volltextzugriff (PDF)

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Journal of the American Academy of Dermatology, 2011-04, Vol.64 (4), p.671-681

2011

Volltextzugriff (PDF)

Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department

The Journal of emergency medicine, 2022-11, Vol.63 (5), p.636-644

2022

Volltextzugriff (PDF)

Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2017-12, Vol.77 (6), p.1038-1046

2017

Volltextzugriff (PDF)

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Journal of the American Academy of Dermatology, 2024-03, Vol.90 (3), p.521-529

2024

Volltextzugriff (PDF)

Psoriasis Area and Severity Index: Nuts and bolts of measuring disease severity in psoriasis

Clinics in dermatology, 2008-11, Vol.26 (6), p.653-656

Okun, Martin M., PhD

2008

Volltextzugriff (PDF)

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Journal of the American Academy of Dermatology, 2006-10, Vol.55 (4), p.598-606

2006

Volltextzugriff (PDF)

Validation of the Physician’s Global Assessment of Fingernail Psoriasis by Rheumatologists Treating Psoriatic Arthritis

Value in health, 2022-09, Vol.25 (9), p.1582-1589

2022

Volltextzugriff (PDF)

Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement

JAMA dermatology (Chicago, Ill.), 2023-11, Vol.159 (11), p.1258

2023

Volltextzugriff (PDF)

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2017-12, Vol.77 (6), p.1030-1037

2017

Volltextzugriff (PDF)

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a Phase II randomized controlled trial

The Journal of dermatological treatment, 2007, Vol.18 (1), p.25-31

2007

Volltextzugriff (PDF)

L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation

Journal of Virology, 2001-05, Vol.75 (9), p.4332-4342

2001

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision

Journal of inherited metabolic disease, 2017, Vol.40 (1), p.75-101

2017

Volltextzugriff (PDF)

Deep brain stimulation in the internal capsule and nucleus accumbens region: responses observed during active and sham programming

Journal of neurology, neurosurgery and psychiatry, 2007-03, Vol.78 (3), p.310-314

2007

Volltextzugriff (PDF)

Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany - a mixed-methods study

Orphanet journal of rare diseases, 2024-05, Vol.19 (1), p.197-197, Article 197

2024

Volltextzugriff (PDF)

Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders

Cell, 2019-12, Vol.179 (7), p.1469-1482.e11

2019

Volltextzugriff (PDF)

Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds

PloS one, 2014-04, Vol.9 (4), p.e95723-e95723

2014

Volltextzugriff (PDF)

Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation

Brain (London, England : 1878), 2021-10, Vol.144 (9), p.2837-2851

2021

Volltextzugriff (PDF)

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial

Annals of internal medicine, 2012-12, Vol.157 (12), p.846

2012

Volltextzugriff (PDF)

The Ontario Birth Study: A prospective pregnancy cohort study integrating perinatal research into clinical care

Paediatric and perinatal epidemiology, 2018-05, Vol.32 (3), p.290-301

2018

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(29)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Female
(19)
Male
(17)
Adult
(15)
Dermatology
(15)
Middle Aged
(13)
Severity Of Illness Index
(10)
Double-Blind Method
(9)
Treatment Outcome
(8)
Adalimumab
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Psoriasis - Drug Therapy
(7)
Antibodies, Monoclonal - Therapeutic Use
(5)
Antibodies, Monoclonal, Humanized
(5)
Quality Of Life
(5)
Aged
(4)
Anti-Inflammatory Agents - Therapeutic Use
(4)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The promise of personalized medicine for hidradenitis suppurativa

Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II

Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department

Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Psoriasis Area and Severity Index: Nuts and bolts of measuring disease severity in psoriasis

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

Validation of the Physician’s Global Assessment of Fingernail Psoriasis by Rheumatologists Treating Psoriatic Arthritis

Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a Phase II randomized controlled trial

L1 Interaction Domains of Papillomavirus L2 Necessary for Viral Genome Encapsidation

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision

Deep brain stimulation in the internal capsule and nucleus accumbens region: responses observed during active and sham programming

Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany - a mixed-methods study

Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders

Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds

Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial

The Ontario Birth Study: A prospective pregnancy cohort study integrating perinatal research into clinical care

Aktive Filter

Suchergebnisse filtern